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Abstract 
Post-translational modifications are induced in stressed cells which cause them to be 
recognised by the immune system.  One such modification is citrullination where the positive 
charged arginine is modified to a neutral citrulline.  We demonstrate most healthy donors 
show an oligoclonal CD4 response in vitro to at least one citrullinated vimentin or enolase 
peptide.  Unlike rheumatoid arthritis patients, these T cell responses were not restricted by 
HLA-DRB1 shared epitope (SE) alleles, suggesting they could be presented by other MHC-II 
alleles.  As HLA-DP is less polymorphic than HLA-DR, we investigated whether the 
common allele, HLA-DP4 could present citrullinated epitopes.  The modification of arginine 
to citrulline enhanced binding of the peptides to HLA-DP4 and induced high frequency CD4 
responses in HLA-DP4 transgenic mouse models.  Our previous studies have shown that 
tumours present citrullinated peptides restricted through HLA-DR4 which are good targets 
for anti-tumour immunity.  In this study we show that citrullinated vimentin and enolase 
peptides also induced strong anti-tumour immunity (100% survival, p<0.0001) against 
established B16 tumours and against the LLC/2 lung cancer model (p=0.034) both expressing 
HLA-DP4.  Since most tumours do not constitutively express MHC class II molecules, 
models were engineered that expressed MHC class II under the control of an IFNγ inducible 
promoter.  Immunisation with citrullinated peptides resulted in 90% survival (p<0.001) 
against established B16 HHD tumour expressing IFNγ inducible DP4.  These studies show 
that citrullinated peptides can be presented by a range of MHC-II molecules, including for the 
first time HLA-DP4, and are strong targets for anti-tumour immunity. 
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Introduction 
The post-translational conversion of arginine residues to citrulline by peptidylarginine 
deiminase (PAD) enzymes requires millimolar concentrations of calcium. 1, 2  This can occur 
during apoptosis leading to precipitation of proteins and stimulation of CD4 and antibody 
responses which are associated with autoimmune diseases such as rheumatoid arthritis (RA). 
3, 4  In RA the presentation of citrullinated epitopes is associated with SE alleles such as 
HLA-DR*0401 (HLA-DR4). 5-7  More recently, citrullination has been shown to occur as a 
result of a degradation and recycling process called autophagy that is induced in stressed 
cells. 8  However, if citrullination is a normal stress response it cannot be restricted to 
individuals only expressing HLA-DR4.  We have previously shown in cancer patients that 
there is a T cell response to citrullinated peptides that is not restricted through the SE alleles.  
We have also shown that potent T cell responses to citrullinated vimentin and enolase in 
HLA-DR4 transgenic mice resulted in strong anti-tumour immunity. 9, 10  This response was 
mediated by killer CD4 T cells which secrete high amounts of IFNγ to upregulate MHC-II 
and then directly kill the tumour cells, without the need for CD8 T cells. 9, 11  We have shown 
that tumour recognition also depends upon autophagy. 9, 10  In this study, we show CD4 
responses in most healthy human donors to at least one citrullinated vimentin and/or enolase 
peptides that are not restricted to the SE allele.  We show enhanced binding of citrullinated 
compared to wild type peptides to HLA-DP4, an allele expressed by over 70% of the 
Caucasian population. 12  In an HLA-DP4 transgenic mouse model we confirm that 
vaccination with the same citrullinated vimentin and enolase peptides can stimulate specific 
CD4 T cell responses which mediate efficient tumour therapy in aggressive lung and 
melanoma models.  This suggests that there is a repertoire of T cells recognising citrullinated 
peptides in healthy donors that can be harnessed for cancer therapy. 
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Results 
Citrullinated peptides stimulate responses in healthy donors  
In our previous studies we demonstrated that citrullinated vimentin and enolase peptide are 
presented by tumour cells since they are targeted by peptide specific T cells and these can be 
targeted for tumour therapy. 9, 10  In these studies we also examined the responses to 
citrullinated vimentin and enolase peptides in humans and demonstrated that individuals 
showed a repertoire of responses to these peptides.  Analysis of the HLA type of these donors 
revealed that responders did not share the HLA-DR*0401 type previously shown to be 
associated with citrullinated peptide specific responses, suggesting the possibility of 
restriction through other HLA alleles.  To determine if repertoires of T cells responding to 
citrullinated peptides that are restricted through alleles other than HLA-DR*0401 exist; we 
examined responses in healthy volunteers to two citrullinated vimentin peptides and one 
citrullinated enolase peptide.  Figure 1Ai shows the presence of significant proliferative 
responses to citrullinated vimentin and enolase peptides when compared to medium alone in 
14/21 (67%) of healthy volunteers.  Figure 1Aii shows more detailed examples of responses 
in some of the donors highlighting that most donors respond to one or more of the 
citrullinated peptides.  Phenotypic analysis of the proliferating responses demonstrated that it 
was CD4+ T cells proliferating in response to the citrullinated peptides rather than CD4 
negative cells (including CD8+ cells).  In addition, these responses appear to be 
predominantly to the citrullinated peptide rather than to the native (wildtype) sequence.  
Representative data for each peptide is shown in Figure 1B.  The citrullinated enolase and 
vimentin peptides have previously been shown to be restricted through HLA-DR*0401. 9, 10, 
13, 14  Analysis of the HLA types of responding donors revealed that of responders only 4/14 
(28%) were known to be HLA-DR*0401 positive (Table 1).  In contrast 10/14 (71%) of the 
responding donors were known to be HLA-DP4 positive with three of unknown HLA type.  
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Only one responding donor, BD0011, was known to be HLA-DP4 negative.  HLA-DP4 is 
known to be expressed by up to 70% of the Caucasian population and therefore developing a 
vaccine relevant to HLA-DP4 positive individuals broadens the use of the vaccine. 
 
Examination of TCR clonality of the responding CD4 T cells revealed a bias of TCR Vβ and 
Vα sequences among CD4+ proliferating cells, CFSElow from donor BD0008 to the vimentin 
28-49cit peptide and from donor BD0011 to the vimentin 415-433cit peptide on comparison 
with the non-proliferating CD4 population.  The TCRα and β CDR3 tree maps from both 
donors demonstrate that the non-proliferating CFSEhigh CD4 cells express highly diversified 
CDR3 nucleotide sequences compared to those expressed in proliferating CFSElow CD4 cells 
that show a dramatic increase in the relative frequency of a subset of CDR3 sequences, 
suggesting a more focused (less diverse) repertoire (Figure 2A-B).  This was confirmed by 
the much lower diversity index (D50) of the CDR3 sequences from the proliferating CD4 T 
cells compared to the non-proliferating CD4 T cells (Table 2) which is a reflection of the 
percent of dominant and unique T clones that account for the cumulative 50% of the total 
CDR3s counted in the sample, where a more diverse library, exhibits a value close to 50. The 
oligoclonal nature of the proliferating CD4 T cells, with a more focused TCR repertoire, is 
further corroborated by the distribution of  the TCRα and β  V usage,  where an increase in 
frequency of a subset of germline V alleles is apparent, in contrast to the non-proliferating 
CD4 cells from the same cultures (Figure 2C-D). 
 
Citrullinated peptides bind to HLA-DP4  
To assess if responses to the citrullinated peptides could be restricted through HLA-DP4, the 
peptides were tested for binding to HLA-DP4.  Binding was compared to a known HLA-DP4 
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restricted peptide from Hepatitis B surface antigen and two peptides from fibrinogen and 
collagen II that have been shown in the literature 15 not to bind to HLA-DP4.  In our assay the 
biotinylated Hepatitis B peptide showed good binding to HLA-DP4 whereas peptides from 
fibrinogen and collagen II demonstrated minimal binding over control (Figure 3A).  The 
unmodified vimentin 415-433 and 28-49 peptides showed low binding to HLA-DP4 that was 
not significant over negative peptides but the citrulline modification dramatically increased 
this binding (p<0.0001) (Figure 3A).  The enolase 241-260 peptide showed binding of the 
unmodified peptide with less difference between binding of the modified and unmodified 
peptides although the binding of the citrulline containing peptide was significantly better than 
the native sequence (p=0.0244) (Figure 3A).  To investigate if the addition of biotin to the 
peptides influenced the binding to HLA-DP4, the binding of the biotinylated Hepatitis B 
peptide was assessed in the presence of an equal amount of non-biotinylated Hepatitis B 
peptide.  The binding was 50% inhibited by an equal amount of non-biotinylated Hepatitis B 
peptide (Figure 3B), thus demonstrating that the addition of biotin to the peptide had little 
effect upon the peptide binding to HLA-DP4.  To further confirm the binding specificity of 
the native (un-biotinylated) peptides for the HLA-DP4 allele, the peptides were added in the 
presence of biotinylated Hepatitis B peptide (previously demonstrated to bind strongly to 
HLA-DP4) and the degree of inhibition evaluated.  The citrullinated vimentin and enolase 
peptides showed a significant inhibition (p<0.0001) of binding of the biotinylated Hepatitis B 
peptide suggesting that they are binding specifically to the HLA-DP4 allele on the membrane 
prep (Figure 3C).  The wildtype peptides and negative control peptides from fibrinogen and 
collagen showed no inhibition of Hepatitis B peptide binding.  In addition to this, the 
citrullinated vimentin and enolase peptides and negative control fibrinogen peptides were 
titrated against a known concentration of biotinylated Hepatitis B peptide.  Figure 3D shows 
that the native Hepatitis B peptide effectively competes with its biotinylated format, with a 
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1:1 ratio of biotinylated to non-biotinylated peptide causing 50% inhibition in signal.  A 
higher amount of the citrullinated vimentin and enolase peptides are required to achieve 50% 
inhibition, suggesting these peptides are of an apparent 2-3 fold lower binding affinity 
compared to the Hepatitis B peptide. 
The enhanced HLA-DP4 binding as a result of the citrulline modification suggests that 
peptide/MHC binding affinity may play a role in the induction of HLA-DP4 restricted 
immune responses to these citrullinated peptides.  However, the modified enolase 241-260 
sequence demonstrated only a small difference in HLA-DP4 binding affinity over the native 
sequence therefore it is possible that other factors such as TCR contact can play a role in the 
generation of HLA-DP4 restricted responses. 
 
Responses to citrullinated peptides can be induced in HLA-DP4 transgenic mice 
In light of the responses in healthy individuals and HLA binding data we screened the two 
citrullinated vimentin and the enolase peptide in a HLA-DP4 transgenic mouse model.  HLA-
DP4 transgenic mice express human CD4 molecule and lack the expression of endogenous 
mouse MHC class I and II alleles which are replaced by transgenic HLA-A2 (HHDII) and 
human HLA-DP4 molecules.  HLA-DP4 transgenic mice were vaccinated with the peptides 
combined with TLR9 and TLR4 agonists, and responses measured ex vivo by IFNγ ELISpot 
assay.  Mice show high frequency responses to the three citrullinated peptides in DP4 
transgenic mice (p<0.0001) with minimal cross reactivity to the wildtype (wt) peptide (Figure 
4A).  Responses are also detected to a known HLA-DP4 peptide from Hepatitis B (Figure 
4Aiv).  No responses to citrullinated peptides are seen in C57Bl/6 mice or HHDII/DR1 
transgenic mice (Supplementary Figure 1) suggesting that these responses were dependent 
upon the HLA-DP4 allele.  To confirm if these responses were CD4 mediated, responses 
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were analysed in the presence of CD4 or CD8 blocking antibodies.  Responses were lost in 
the presence of the CD4 blocking antibody (p<0.0001 for vimentin 28-49cit and enolase 241-
260cit, p=0.0002 for vimentin 415-433cit) but not affected to the same extent in the presence 
of the CD8 blocking antibody suggesting these are CD4 mediated responses in the DP4 
transgenic mice (Figure 4B).  The vimentin 28-49 sequence is homologous between humans 
and mice, however, the vimentin 415-433 and enolase 241-260 sequences have two and one 
amino acid differences respectively between the human and murine sequences therefore 
responses induced with the human peptide sequences were checked for cross reactivity to the 
murine homologues in DP4 transgenic mice (Figure 4C).  Responses to both human 
sequences showed cross reactivity to the murine counterparts.   In addition to this mice were 
immunised with the murine peptide sequences and showed the generation of responses 
specific to the citrullinated peptides and not to the wt (Supplementary Figure 2).  This 
confirms that the human peptides behave similarly to the murine peptides and were suitable 
for study in the mouse model.    Peptides used encompassed 19-21 amino acids. In an attempt 
to map a shorter peptide sequence for each epitope, responses induced with the vimentin 28-
49cit, 415-433cit and enolase 241-260cit peptides were tested for reactivity to shorter 
peptides spanning the longer sequences.  Responses showed cross reactivity with the shorter 
peptide epitopes vimentin 28-42cit, 418-431cit and enolase 241-255cit in the DP4 transgenic 
mice where similar levels of responses were seen (Figure 4D).  This was consistent with 
findings in the DR4 transgenic mice mapping shorter peptide sequences to vimentin 418-431, 
vimentin 28-42 and enolase 241-255 (Supplementary Figure 3). 
 
Citrullinated peptides provide efficient tumour therapy against B16 tumours in both 
HLA-DR4 and HLA-DP4 transgenic mice 
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We have previously shown that citrullinated vimentin and enolase peptides presented by 
tumour cells can be good targets for CD4 T cells and these provide good tumour therapy in 
HLA-DR4 transgenic models.  The B16 tumour model lacking endogenous murine MHC 
class I and II alleles was engineered to express HHDII and HLA-DP4 for use in HLA-DP4 
transgenic mice.  Cell lines engineered to express inducible HLA-DR4 or HLA-DP4 
demonstrated a similar growth rate in the transgenic mice compared the parental B16F1 line 
in C57Bl/6 mice (p=0.5673 and p=0.2166 respectively).  The engineered models also 
demonstrated no significant difference in overall survival (Supplementary Figure 4).  To 
determine if responses to the citrullinated peptides induced similar anti-tumour responses in 
HLA-DP4 mice to HLA-DR4 mice, we challenged mice with tumour and subsequently 
vaccinated with citrullinated or wildtype peptide plus adjuvant.  Each of the three 
citrullinated peptides in combination with TLR9/TLR4 ligands provided tumour therapy in a 
B16 melanoma model constitutively expressing HLA-DP4 or HLA-DR4 that was 
significantly better than the wildtype peptide (Figure 5A), suggesting that these epitopes are 
presented in this tumour model.  A study was also performed with the murine peptide 
sequences confirming that the similar immune responses also translate to tumour therapy 
(Supplementary Figure 5).  These responses were as effective in the HLA-DP4 model as in 
the HLA-DR4 model (Figure 5A).  The combination of all three citrullinated peptides 
provided 100% survival in the HLA-DP4 transgenic mouse model (p>0.0001) (Figure 5B).  
Since most tumours do not constitutively express MHC class II molecules a model was 
engineered that expressed HLA-DP4 under the control of an IFNγ-inducible promoter.  
Analysis of the combination of citrullinated peptide specific responses induced in the 
presence of TLR9/TLR4 ligands in the tumour model expressing HLA-DP4 under the 
inducible promoter showed efficient tumour therapy (p<0.0001) even when expression of 
MHC class II on the tumour requires induction by IFNγ (Figure 5C).  Since CD4 T cells can 
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have both direct and indirect (via effects on infiltrating APCs and CD8 T cells)  impact on the 
tumour, the role for direct recognition of the tumour by CD4 T cells was also assessed by the 
use of a tumour model unable to express HLA-DP4 (Figure 5D).  No tumour therapy was 
seen when the tumour cells were unable to express HLA-DP4 suggesting that the tumour 
cells present the citrullinated peptides on HLA-DP4 which are a direct target for CD4 T cell 
responses.  To examine the efficacy of the immune response against established tumours 
HLA-DP4 mice were given a single immunisation of the three citrullinated peptides at either 
3, 7 or 14 days post tumour implant.  Single immunisations at days 3, 7 or 14 were able to 
efficiently prevent tumour growth and resulted in 90% (p<0.0001), 60% (p=0.0023) and 40% 
(p=0.025) survival respectively (Figure 5E). 
 
Citrullinated peptides also provide efficient tumour therapy against lung tumours in 
both HLA-DP4 and HLA-DR4 transgenic mice 
Vimentin and enolase are proteins expressed by many cells and are therefore potential targets 
for treatments of a wide range of cancers.  In addition to the B16 melanoma model, we 
examined the effect of the citrullinated peptides in combination with TLR9/TLR4 ligands for 
the therapy of the murine LLC/2 lung tumour line in the HLA-DR4 and HLA-DP4 mouse 
models.  LLC/2 cells were shown to be positive by Western blot for the expression of 
vimentin and enolase (Supplementary Figure 6).  Immunisation of mice in the HLA-DP4 
model with the combination of two citrullinated vimentin peptides and the citrullinated 
enolase peptide showed significant delay in tumour growth over control (p<0.0001) in the 
aggressive lung tumour model expressing HLA-DP4 (Figure 6A).  The two citrullinated 
vimentin peptides or the citrullinated enolase peptide also showed significant delay in tumour 
growth (p=0.034 and p=0.0456) of the aggressive lung tumour model in HLA-DR4 mice 
(Figure 6B). 
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Discussion 
Citrullinated peptides have been shown to be presented on MHC class II via autophagy in 
antigen presenting cells. 8  We have shown a similar mechanism in tumour cells whereby as a 
result of autophagy citrullinated peptides are presented in the context of HLA-DR*0401 and 
recognised by cytotoxic CD4 T cells. 9  As autophagy is increased under stressful conditions 
it seemed plausible that citrullinated peptides could be a general mechanism to alert the 
immune system to recognise and remove stressed cells.  The assumption is therefore that 
citrullinated peptides must be presented on a range of HLA alleles.  In this study we show 
that most healthy donors show a CD4 T cell response to one or more citrullinated vimentin 
and enolase peptides suggesting that this is a common occurrence.  The proliferation 
responses were highly oligoclonal and different between peptides suggesting that these cells 
were selectively responding to each peptide.  In contrast, the non-proliferating cells had a 
very diverse repertoire suggesting that they had not responded.  Indeed, the predominant 
clones in the proliferating cells were poorly represented in the non-proliferating cells.  
Citrullinated peptides can be presented in the thymus 16 but responses in healthy donors 
suggested that the T cells recognising them are positively but not negatively selected.  
Previous studies in RA patients have shown that citrullinated peptides are predominantly 
expressed by SE alleles, 3, 13, 17 but in line with our previous studies 9, 10 the healthy donors in 
this study did not show this restriction.  Indeed, the best correlation with response was 
expression of the HLA-DP4 restriction with 71% of the responding donors known to express 
this haplotype and 21% of unknown haplotype.  Only one responding donor was known to be 
SE and HLA-DP4 negative.  There have been limited publications suggesting citrullinated 
peptides can also preferentially bind to HLA-DR9 and HLA-DQ2,7 and 8. 18, 19  None of our 
donors expressed HLA-DR9, HLA-DQ7 or HLA-DQ8.  43% of the responding donors 
expressed HLA-DQ2 with 21% unknown  suggesting these alleles could have presented the 
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citrullinated peptides in these donors.  There are no previous reports of HLA-DP4 presenting 
citrullinated peptides. 
To confirm this observation, we showed that the citrullinated peptides bound more strongly to 
HLA-DP4 than the arginine containing peptides.  It has been previously thought that the 
conversion of arginine to citrulline enhances the binding of some peptides to HLA-DR and 
DQ alleles. 19, 20  In contrast it has also been shown that the conversion of arginine to 
citrulline does not always lead to enhanced peptide MHC class II binding affinity. 15  We 
have also shown that HLA-DP4 transgenic mice make strong Th1 responses to human 
citrullinated vimentin and enolase peptides that do not cross react with wild type peptides.  
These responses also cross react with the homologous murine sequences suggesting a 
breaking of tolerance similar to the scenario that would be encountered in human patients.  
Increasing evidence is emerging that HLA-DP molecules can present epitope peptides in the 
context of infectious disease, allergy and cancer. 21-24  HLA-DP alleles appear more 
conserved than DR or DQ alleles, with 5 alleles frequently expressed in the worldwide 
population that cover approximately 90% of individuals. 25  Recent evidence also suggests 
that these common HLA-DP alleles can share a HLA supertypic binding specificity. 25  It is 
therefore possible that the citrullinated peptides discussed could show binding to other HLA-
DP alleles in addition to HLA-DP4.  Since citrullination occurs in times of cellular stress and 
these ‘stressed cells’ would require clearance by the immune system, the potential to alert the 
immune system to this through presentation of citrullinated peptides via MHC class II would 
be beneficial.  Therefore, the reduced polymorphism among HLA-DP alleles suggests these 
as prime candidates for presentation of peptides in this universal process and may point to a 
role of HLA-DP alleles in the clearance of stressed cells.  Indeed van Lith et al. have shown 
that HLA-DP does not require invariant chain or HLA-DM to form stable dimers making it 
more accessible to peptides produced during autophagy. 26, 27  Other studies have shown that 
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HLA-DP4 does not bind CLIP fragments, 28 and known HLA-DP peptide-binding motifs 
differ from those of (ER-loaded) MHC molecules, so DP is not likely to compete for classical 
class II-binding peptides. 29  The reported lower expression of HLA-DP molecules 30, 31 most 
likely plays a role to avoid autoimmunity and promote self-tolerance.  In contrast, co-
expression on HLA-DP4 and HLA-DR4 may push T cells over the threshold and result in 
autoimmune disease. 
Our responding healthy donors and our HLA-DP4 transgenic mice immunised with the 
citrullinated vimentin and enolase peptides induced CD4 T cell responses.  These CD4 T 
cells mediated, anti-tumour immunity in HLA-DP4 transgenic mice against B16 tumours 
expressing either constitutive or IFNγ inducible HLA-DP4.  CD4 T cells are also able to exert 
indirect effects upon the tumour via the activation of M1 macrophages and provision of help 
for CD8 T cells. 32-34  To address this possibility, a model was used where the tumour cells 
did not express the relevant MHC class II allele .  The loss of tumour therapy in the absence 
of MHC class II expressed by the tumour implies in this model that the anti-tumour effect is 
mediated by direct effects of the CD4 T cells upon the tumour.  The anti-tumour immunity 
was similar in HLA-DP4 and HLA-DR4 mice suggesting both alleles can equally present the 
citrullinated epitopes on tumours.  Indeed, a single immunisation with the combination of 
citrullinated vimentin and enolase peptides induced significant anti-tumour immunity even 14 
days after tumours were established.  To show that these anti-tumour responses were not 
restricted to B16 melanoma, similar results were also obtained against the HLA-DP4 
expressing Lewis lung carcinoma line, LLC/2.  Immunised mice demonstrating strong 
tumour rejection showed no evidence of toxicity suggesting healthy cells do not present 
these modified epitopes.  Indeed, it has been shown that RA cannot be induced by T cells 
alone but requires joint erosion, antibody responses and inflammation.  This is borne out 
by studies where no autoimmune symptoms were observed with T cells alone, even in 
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HLA-DR4 transgenic mice which are susceptible to RA. 35  Our studies suggest 
citrullinated vimentin and enolase peptides could be used to stimulate strong anti-tumour 
immune responses in both HLA-DR4 and HLA-DP4 individuals.  
 
Materials and Methods 
Laboratory practice 
These studies were conducted in a laboratory that operates under exploratory research 
principles.  Standard operating procedures were used for all human and mouse T cell assays.  
These studies were performed using general research investigative assays.  Procedures and 
raw data can be obtained from Scancell Ltd through corresponding author and may be subject 
to non-disclosure agreements.  Unless otherwise stated all reagents were obtained from 
Sigma-Aldridge. 
 
Cell lines and culture 
The murine melanoma B16F1 cell line (ATCC-CRL-6323) and murine lung carcinoma line 
LLC/2 (ATCC-CRL-1642) were obtained from the American Type Culture Collection 
(ATCC).  B16F1 cell line was cultured in RPMI medium 1640 (GIBCO/BRL) supplemented 
with 10% Fetal Calf Serum (FCS), L-glutamine (2mM) and sodium bicarbonate buffered; 
LLC/2 was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% FCS.  The cell lines utilised were certified mycoplasma free, authenticated by suppliers 
(STR profiling) and used within ten passages. 
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Peptides and adjuvants 
Peptides vimentin amino acid (aa)28-42cit (cit-SYVTTST-cit-TYSLGS), aa28-42wt 
(RSYVTTSTRTYSLGS), aa28-49wt (RSYVTTSTRTYSLGSALRPSTS), aa28-49cit (cit-
SYVTTST-cit-TYSLGSAL-cit-PSTS), human aa28-42cit (cit-SYVTTST-cit-TYSLGS), 
human aa32-46cit (TTST-cit-TYSLGSAL-cit-P), human aa415-433wt 
(LPNFSSLNLRETNLDSLPL), human aa415-433cit (LPNFSSLNL-cit-ETNLDSLPL), 
mouse aa415-433wt (LPTFSSLNLRETNLESLPL), mouse aa415-433cit (LPTFSSLNL-cit-
ETNLESLPL), human aa418-431cit (FSSLNL-cit-ETNLDSL), human enolase aa241-260cit 
(VIGMDVAASEFF-cit-SGKYDLD), human aa241-260wt 
(VIGMDVAASEFFRSGKYDLD), mouse aa241-260cit (VIGMDVAASEFY-cit-
SGKYDLD), mouse aa241-260wt (VIGMDVAASEFYRSGKYDLD), human aa 241-255cit 
(VIGMDVAASEFF-cit-SG), human aa 246-260cit (VAASEFF-cit-SGKYDLD), ),  
fibrinogen aa78-91cit (NQDFTN-cit-INKLKNS), collagen II aa1236-1249cit (LQYM-cit-
ADQAAGGLR) 15 and Hepatitis B surface antigen aa 181-193 36 were synthesized at >90% 
purity by Genscript (USA) and stored lyophilised at -80C.  On the day of use they were 
reconstituted to the appropriate concentration in phosphate buffered saline (PBS). 
Adjuvants used include TLR9 agonist CpG ODN 1826 (Invivogen) and TLR4 agonist 
monophosphoryl lipid A (MPLA; Sigma); both  used at a dose of 5µg/mouse/immunisation. 
 
Plasmids 
The construction of the plasmid pVITRO2 Chimeric HLA-DR401 and the IFNγ inducible 
plasmid pDCGAS chimeric HLA-DR401 have been described previously. 9  The HHDII 
plasmid pCDNA3 HHDII is described in detail elsewhere. 37 
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To generate the plasmid pVITRO2 Human HLA-DP4, the nucleotide sequence encoding the 
full length human HLA-DPA*0103 α chain flanked by FspI/EcoRI and the HLA-DPB*0401 
β chain flanked by BamHI/SalI restriction sites were synthesized (Eurofins MWG).  
Following sequence confirmation, the HLA-DPA*0103 chain was cloned into the FspI/EcoRI 
mcs2 of the vector pVITRO2-hygro-mcs (Invivogen).  The HLA-DPB*0401 chain was 
subsequently inserted into the BamHI/SalI mcs1 of the mammalian expression vector 
alongside the alpha HLA-DPA*0103 chain present within mcs2.  To construct the IFNγ 
inducible plasmid pDCGAS Human HLA-DP4, the HLA-DPA*0103α and HLA-DPB*0401β 
chains, were sequentially cloned into the pDCGAS chimeric HLA-DR401 plasmid in 
replacement of the chimeric DR4 chains described elsewhere. 9  The IFNγ inducible promoter 
within this plasmid consists of a TATA box and the GAS (IFNγ activated sequence) direct 
repeat enhancer element that in the presence of IFNγ drives expression of the HLA-DP401 
chains within the pDCOrig vector backbone.  After sequence confirmation endotoxin free 
plasmid DNA was generated using the endofree Qiagen maxiprep kit (Qiagen, Crawley). 
 
Transfection and flow cytometry 
B16F1 melanoma and LLC/2 lung carcinoma cells expressing HLA-DR4 under expression of 
the constitutive and IFNγ inducible promoters have been described previously. 9 
The B16F1 cell line previously knocked out for murine MHC class I and II by Zinc finger 
Technology (Sigma Aldrich) was transfected using Lipofectamine LTX with plus reagent 
(Invitrogen), with 4µg of each plasmid, pCDNA3 HHDII in combination with either the 
pVITRO2 Human HLA-DP4 or pDCGAS Human HLA-DP4 plasmids, where DP4 is under 
expression of the constitutive or IFNγ inducible promoter, respectively.  Transfected cells 
were selected by growth in the presence of G418 (500µg/ml) with either Hygromycin B 
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(300µg/ml) or Zeocin (300µg/ml).  The LLC/2 lung carcinoma cell line was also transfected 
with the pVITRO2 Human HLA-DP4 plasmid and selected on incubation with media 
supplemented with Hygromycin B (300µg/ml).  Lines were cloned by limiting dilution and 
expression was confirmed by flow cytometry using the anti-human beta 2 microglobulin 
FITC (clone TU19, BD Biosciences) and anti-human HLA-DR/DP/DQ (clone WR18, 
Abcam) PE antibodies.  Cells transfected with the IFNγ inducible plasmid where incubated 
overnight in the absence or presence of murine IFNγ (50ng/ml, Gibco Life Technologies) 
prior to staining with the antibody. 
 
HLA-DR4 and DP4 binding studies 
Binding to HLA-DP4 was assessed by extraction of membrane fractions from 
B16HHDII/DP4 cells using Mem-PER™ Plus Membrane Protein Extraction Kit 
(Thermofisher-Scientific) according to manufacturer’s instructions.  Membrane preps 
containing HLA-DP4 were incubated with 10µg biotinylated peptide at for 4hrs at 37˚C.  For 
competition assays the 10µg biotinylated Hepatitis B peptide was incubated in the presence 
of specified concentrations of non-biotinylated peptides.  Biotinylated peptide bound to HLA-
DP4 was visualised by capture onto streptavidin coated ELISA plates and detected with anti-
HLA-DP antibody clone B7/21 (Leinco Technologies Inc, USA) and anti-mouse IgG3 HRP 
antibody (Invitrogen, UK).  Binding was quantified with TMB substrate and absorbance read 
at 405nm wavelength.  
 
Immunisation protocol 
HLA-DR4 mice (Model #4149, Taconic), HLA-A2.1+/+ HLADP4+/+ hCD4+/+ (HLA-DP4) 
transgenic mice (EM:02221, European Mouse Mutant Archive), HHDII/DR1 mice (Pasteur 
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Institute) or C57Bl/6 mice (Charles River) aged between 8 and 12 weeks were used.  All 
work was carried out under a Home Office approved project license.  For all studies the mice 
were randomised into different groups but not blinded to the investigators.  Peptides were 
dissolved in PBS and then emulsified with CpG (ODN 1826) and MPLA and delivered at 
25µg dose unless stated otherwise.  Adjuvants were used at 5µg/dose.  Peptides in adjuvant 
were injected subcutaneously at the base of the tail.  Mice were immunised on day 0, 7 and 
14 and spleens were removed for analysis at day 20. 
For tumour challenge experiments mice were challenged with 2.5x104 B16 DR4 cells, 4x105 
B16 HHDII DP4 cells, 1.5x106 LLC/2 DR4, 2.5x106 LLC/2 DP4, 5x104 B16 inducible DR4 
or 1x105 B16 HHDII inducible DP4 cells subcutaneously on the flank 3 days prior to primary 
immunisation and then immunised as above unless stated otherwise.  Tumour growth was 
monitored at 3-4 days intervals and mice were humanely euthanised once tumour reached 
≥10 mm in diameter.  Tumour volume was estimated using the following formula, volume = 
(π/6)x(LxW2), where L is length and W is width. 
 
Ex vivo ELISpot assay 
ELISpot assays were performed using murine IFNγ capture and detection reagents according 
to the manufacturer’s instructions (Mabtech).  In brief, the IFNγ specific antibodies were 
coated onto wells of 96-well Immobilin-P plate.  Synthetic peptides (10µg/ml) and 5x105 per 
well splenocytes were added to the wells of the plate in quadruplicate and plates incubated 
for 40hrs at 37˚C in an atmosphere of 5% CO2.  Where relevant anti-CD4 (mouse clone 
GK1.5 or human clone OKT4, BioXcell) or CD8 (mouse clone 2.43, BioXcell) blocking 
antibodies were added to splenocytes at 20µg/ml for 15 minutes prior to stimulation with 
peptide.  Lipopolysaccharide (LPS) at 5µg/ml was used as positive control.  After incubation, 
captured IFNγ was detected by biotinylated specific IFNγ antibodies and developed with a 
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streptavidin alkaline phosphatase and chromogenic substrate.  Spots were analysed and 
counted using an automated plate reader (Cellular Technologies Ltd). 
 
Peripheral blood mononuclear cell (PBMC) isolation 
PBMC experiments were carried out with ethical approval.  Demographics of healthy donors 
are shown in Table 1.  Peripheral blood samples (approx. 50ml) were drawn into lithium 
heparin tubes (Becton Dickinson).   Samples were maintained at room temperature and 
processed immediately following venepuncture.  PBMCs were isolated by density gradient 
centrifugation using Ficoll-Hypaque.  Proliferation assays were performed immediately after 
PBMC isolation.  The median number of PBMCs routinely derived from healthy donors was 
1.36 x 106 PBMC/ml whole blood (range 0.6 x 106 – 1.8 x 106 /ml).  The median viability as 
assessed by trypan blue exclusion was 90.6% (range 80-97%).  For CD25 depletion PBMCs 
were processed as above and then immediately enriched with anti-CD25 microbeads and 
MACS cell separation columns (Miltenyi). 
 
Proliferation assay 
CD25 depleted PBMCs were subjected to carboxyfluorescein succinimidyl ester (CFSE; 
Thermofisher) labelling with 5µM CFSE for 5 minutes at room temperature in PBS 5% FCS 
followed by a wash in a 10-fold excess of PBS 5% FCS.  Cells were resuspended at 1.5-
2x106/ml, cultured with 10μg/ml peptide or vehicle (negative control) and analysed at days 7 
and 11 for dilution of CFSE by flow cytometry combined with staining for CD4 (efluor 450 
clone RPA-T4, Thermofisher) and CD8 (APC clone RPA-T8, Thermofisher).   
At day 10 post-stimulation, cells for TCR analysis were stained for CD4 (efluor 450 clone 
RPA-T4, Thermofisher) and CD8 (APC clone RPA-T8, Thermofisher) and subsequently 
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sorted on a MoFlow Cell Sorter (Beckman Coulter) into CD4+ve/CFSEhigh and 
CD4+ve/CFSElow populations. Populations were sorted directly into 1.0ml of RNA protect 
reagent (Qiagen) diluted 5:1 with FACS sorting buffer (PBS supplemented with 1mM EDTA, 
20mM HEPES and 1% FCS) . Samples were stored at -80oC until analysis 
 
RT-PCR, NGS bulk sequencing of the TCR α and β chains and repertoire data analysis 
Sorted cells (bulk) from CD4+ve/CFSEhigh and CD4+ve/CFSElow populations in RNA protect 
(Qiagen) were shipped to iRepertoire Inc (Huntsville, AL, USA) for NGS sequencing of the 
TCR α and TCR β chain to confirm expansion of TCR’s in the CD4+ve/CFSElow cells, 
proliferating to the peptide in contrast to the non-proliferating CD4+ve/CFSEhigh population.  
In brief RNA was purified from sorted cells, RT-PCR was performed, cDNA was then 
subjected to Amplicon rescued multiplex PCR (ARM-PCR) using human TCR α and β 250 
PER primers (iRepertoire Inc., Huntsville, AL, USA).  Information about the primers can be 
found in the United States Patent and Trademark Office (Patent Nos. 7,999,092 and 
9,012,148B2).  After assessment of PCR/DNA samples, 10 sample libraries were pooled and 
sequenced using the Illumina MiSeq platform (Illumina, San Diego, CA, USA).  The raw 
data was analysed using IRweb software (iRepertoire). V, D, and J gene usage and CDR3 
sequences were identified and assigned D50 diversity values and tree maps generated using 
iRweb tools.  Tree maps show each unique CDR3 as a coloured rectangle, the size of each 
rectangle corresponds to each CDR3s abundance within the repertoire and the positioning is 
determined by the V region usage.  Diversity was measured using D50 immune repertoire 
diversity index. The D50 index is a quantitative measure of the degree of diversity of T cells 
within a sample. The D50 is the percentage of T-cell clones that account for the cumulative 
50% of the total CDR3s counted in the sample. The more diverse a library, the closer the 
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value will be to 50. Low diversity values are associated with decreased diversity. Data are 
presented as non-normalised (which takes into account the frequency of each unique CDR3). 
 
Statistical analysis 
Comparative analysis of the ELISpot and peptide binding assay results was performed by 
applying paired or unpaired ANOVA or Students t test as appropriate with values of P 
calculated accordingly.  Sidak correction for multiple comparisons was applied where 
relevant in analysis of Elispot data and Tukey correction for multiple comparisons was 
applied where relevant in analysis of peptide binding data.  Comparison of tumour survival 
was assessed by Log Rank (Mantel-Cox) test and tumour size was assessed by Mann-
Whitney test using the Graphpad Prism software version 7.  P < 0.05 values were considered 
statistically significant and p < 0.01 values were considered highly significant.  The error bars 
shown in the figures represent the mean + standard deviation. 
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Figure 1.  Characterisation of responses to citrullinated peptides in healthy donors.  A, 
Healthy donor PBMCs were analysed for proliferation in response to citrullinated vimentin or 
enolase peptides.  Results shown as percentage proliferating CD4+ cells shown for each 
peptide (i) and each donor (ii).  B, Example dot plots showing proliferation of CD4 cells in 
response to citrullinated and native peptides.  Results are representative of at least two 
independent experiments.   
 
Figure 2.  TCR α and β repertoire diversity in CD4+ve CFSE high/low cells responding to 
citrullinated peptides.  Tree maps depicting TCR α and β chain CDR3 clonotype usage in 
relation to repertoire size in CD4+ve CFSE high/low cells on incubation with citrullinated 
peptides vimentin 28-49 from donor BD0011 (A) and vimentin 415-433 from donor 
BD0008(B).  Each rectangle in a tree map represents a unique CDR3 nucleotide sequence 
and the size of each rectangle denotes the relative frequency of an individual sequence.  The 
colours for the individual CDR3 sequences in each tree map plot are chosen randomly and 
thus do not match between plots.  Histogram showing % expression of TCRVα (i) and 
TCRVβ (ii) chains among proliferating and non-proliferating CD4+ve cells in donors BD0008 
(C) and BD0011 (D) to citrullinated peptides vimentin 28-49 and vimentin 415-433.  
 
Figure 3.  Citrullinated peptides bind to HLA-DP4.  Direct binding of biotinylated 
citrullinated and native peptides to HLA-DP4 (A).  Binding of 10µg biotinylated Hepatitis B 
(HepB) peptide in the presence and absence of 10µg non-biotinylated HepB 181-193 peptide 
(B).  Competition of 40µg non-biotinylated competitor peptides in the presence of 10µg 
biotinylated HepB 181-193 peptide (C).  Titration of non-biotinylated competitor peptide 
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with 10µg biotinylated HepB 181-193 peptide (D).  Results are representative of at least two 
independent experiments. 
 
Figure 4.  Citrullinated vimentin and enolase peptides stimulate CD4 responses in HLA-DP4 
transgenic mice.  HLA-DP4 transgenic mice were immunised with citrullinated Vim28-49 
(ii), Vim415-433 (i), Eno241-260 peptides (iii) or HepB 181-193 (iv) and immune responses 
specific to the citrullinated or native peptides were monitored by IFNγ Elispot assay and 
compared to control (A).  Immune responses were assessed in the presence of CD4 or CD8 
blocking antibodies (B).  Immune responses to the citrullinated human Eno241-260 and 
Vim415-433 peptides were tested for cross reactivity to the murine peptides (C).  Immune 
responses in HLA-DP4 mice were mapped to shorter peptide sequences (D).  Results are 
representative of at least two independent experiments in which n=3. 
 
Figure 5.  Citrullinated vimentin and enolase peptide vaccination provide tumour therapy in 
HLA-DR4 and DP4 transgenic mice.  A, HLA-DP4 or DR4 transgenic mice were challenged 
with B16 cells constitutively expressing DP4 or DR4 and four days later mice were 
immunised with citrullinated or native Vim28-49, Vim415-433 or Eno241-260 peptides and 
tumour growth and survival monitored.  HLA-DP4 transgenic mice were challenged with 
B16 cells constitutively expressing DP4 (C), expressing DP4 under an IFNγ inducible 
promoter (C) or expressing no DP4 (D) and four days later mice were immunised with 
combination of citrullinated Vim28-49, Vim415-433 and Eno241-260 peptides and tumour 
growth and survival monitored.  E, HLA-DP4 transgenic mice were challenged with B16 
cells expressing DP4 under an IFNγ inducible promoter followed by a single vaccination at 
days 3, 7 or 14.  Tumour growth and survival was monitored. N=10/group. 
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Figure 6.  Citrullinated peptides provide efficient therapy of lung tumours.  HLA-DP4 (A) or 
DR4 (B) transgenic mice were challenged with LLC/2 cells constitutively expressing DP4 or 
DR4.  Four days later mice were immunised with citrullinated Vim28-49, Vim415-433 and 
Eno241-260 peptides and tumour growth monitored.  Tumour growth curves (i) and tumour 
volume (ii) in the DP4 model at day 15 and in DR4 model at day 16 are shown.  N=10/group. 
 
Table 1. HLA typing of healthy donors 
Donor Sex Age HLA-A HLA-B HLA-C HLA-DR 
HLA-
DQ 
HLA-
DP 
BD0025 F 40-50 2,29 7,57 6,7 1,7,53a 3,5 3,13 
BD0016 
M 50-60 
1,2 8,44 5,7 
3,15, 51a, 
52a 
2,6 1,4 
BD0008 M 50-60 1 8 7 3 2 1,4 
BD0002 M 40-50 2,29 44,51 ND 7,11 2, 3 4,5 
BD0026 
M 30-40 
2 7,41 7,17 
7,13,52a, 
53a 
2,3 1,4 
ND04 F 30-40 3,24 15,27 2,3 4, 53a 3 4,9 
ND07 F 20-30 2,29 15,44 3,16 4,7, 53a 2,3 2 
BD0007 
F 30-40 
1, 32 8, 15 7 
3, 13, 
51a,51c 
2, 6  4,13 
BD0024 
F 30-40 
2 7,27 1,7 
4,15,53a, 
51a 
3,6 4 
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BD0027 M 40-50 1,11 8,57 6,7 7,8 3,4 4 
BD0011 M 20-30 33,74   18,49 07  13,15  05,06  17,18  
BD0003 M 40-50 11,29 ND  ND  4,13 3,6 4 
ND11 M 40-50 02,03  07,40  03,07  12,13  03,06   02,04 
BD0038 F 30-40 26,33   40,58 03,03  09,11  03,03  04,05  
BD0014 F 30-40  Not available          
BD0006 F 20-30 Not available           
BD0015 F 40-50 03,24  07,15  03,07  04,15  03,06   04 
BD0022 F 30-40 01,02  35,50  06,12  04,07  02,03  02,04  
BD0031 M 20-30  Not available          
BD0041 F 50-60 01,24  07,40   03,07 04,11   03,03  02,04 
BD0044 F 20-30  Not available          
Grey highlight = responding donors, M=male, F=female 
 
Table 2. CDR3 diversity values for the TCR α and β chain from the CD4+ CFSEhigh and 
CFSElow cells obtained from donors incubated with peptides 
DONOR PEPTIDE SAMPLE 
Diversity Index 
(D50) 
TRA TRB 
BD0008 Vimentin 28-49 cit CD4+ CFSEHigh 12.8 17 
    CD4+ CFSELow 0.4 0.2 
BD0011 Vimentin 415-433 cit CD4+ CFSEHigh 9.9 5.9 
    CD4+ CFSELow 0.7 0.5 
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Supplementary Figure 1. 
Supplementary Figure 1.  C57Bl/6 or HHDII/DR1 transgenic mice were immunised with 
citrullinated Vim28-49, Vim415-433 or Eno241-260 peptides and immune responses specific 
to the citrullinated or wt peptides were monitored by IFNγ Elispot assay. 
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Supplementary Figure 2 
  
Supplementary Figure 2.  HHDII/DP4 transgenic mice were immunised with citrullinated 
murine (Mo) Vim415-433 or murine Eno241-260 peptides and immune responses specific to 
the citrullinated or wt peptides were monitored by IFNγ Elispot assay 
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Supplementary Figure 3 
 
Supplementary Figure 3.  HLA-DR4 transgenic mice were immunised with citrullinated 
Vim28-49, Vim415-433 or Eno241-260 peptides and immune responses were mapped to 
shorter peptide sequences in IFNγ Elispot assay. 
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Supplementary Figure 4 
 
Supplementary Figure 4.  C57Bl/6 mice, HLA-DP4 or HLA-DR4 transgenic mice were 
challenged with B16 cells or B16 cells expressing inducible DP4 or inducible DR4 respectively 
and growth and survival was monitored.  Data is combined from at least 3 independent studies 
where N>5/group. 
 
  
Supplementary Figure 5 
 
Supplementary Figure 5.  HLA-DP4 transgenic mice were challenged with B16 cells 
expressing inducible DP4 followed by vaccination on days 4, 11 and 18 with citrullinated or 
wt Vim28-49, murine Vim415-433 or murine Eno241-260 and growth and survival was 
monitored.  Data is combined from studies where N=10/group. 
 
  
Supplementary Figure 6 
 
Supplementary Figure 6. Expression of vimentin and enolase in murine tumour or human cell 
lines in Western blot using antibodies to vimentin and Enolase (Abcam) (A). Normalised 
fluorescence signal relative to actin control (B).   
 
